[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546453":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":35,"centralContacts":40,"locations":48,"responsibleParty":149,"collaborators":151,"id":175,"slug":176,"hasResults":177,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":10,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":183,"minAge":184,"maxAge":10,"enrollmentInfo":185,"targetDuration":10,"studyType":188,"phases":10,"briefSummary":189,"conditions":190,"keywords":194,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},{"fullName":5,"class":6},"Médecins du Monde","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort study",null,"All participants in the cohort study will undergo surveys, HIV, and HCV testing at four possible timepoints (baseline, 6-months, 12-months, and if time permits 18-months).\n\nThey will also have access to the study sites usual services, and the introduced LDSS\u002FN.",[13,14,15],"Device: Low dead-space syringes\u002Fneedles","Device: Hepatitis C Antibody Rapid Diagnostic Test","Device: HIV rapid Diagnostic Test",[17,24,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DEVICE","Low dead-space syringes\u002Fneedles","LDSS\u002FN are a type of syringe\u002Fneedle which retains less residual blood following an injecting event when compared to HDSS\u002FN.",[9],[23],"LDSS\u002FN",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Hepatitis C Antibody Rapid Diagnostic Test","Administered up to 4 times, at baseline, 6-months, 12-months, and 18-months",[9],[29],"HCV RDT",{"type":18,"name":31,"description":26,"armGroupLabels":32,"otherNames":33},"HIV rapid Diagnostic Test",[9],[34],"HIV RDT",[36],{"name":37,"affiliation":38,"role":39},"Mark Stoové","Burnet","PRINCIPAL_INVESTIGATOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":10,"email":45},"Bridget Draper","CONTACT","+61 413 272 698","bridget.draper@burnet.edu.au",{"name":37,"role":43,"phone":10,"phoneExt":10,"email":47},"mark.stoove@burnet.edu.au",[49,65,79,89,99,112,119,129,139],{"facility":50,"status":51,"city":52,"state":10,"zip":10,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Real World Real People","RECRUITING","Yerevan","Armenia","AM",{"type":56,"coordinates":57},"Point",[58,59],44.5126,40.17765,{"lat":59,"lon":58},[62],{"name":63,"role":43,"phone":10,"phoneExt":10,"email":64},"Tamara Ohanjanyan","pm.cutts.armenia@medecinsdumonde.net",{"facility":66,"status":51,"city":67,"state":10,"zip":10,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Step to Future","Gori","Georgia","GE",{"type":56,"coordinates":71},[72,73],44.1129,41.98532,{"lat":73,"lon":72},[76],{"name":77,"role":43,"phone":10,"phoneExt":10,"email":78},"Lasha Abesadze","lashaabes@gmail.com",{"facility":80,"status":51,"city":81,"state":10,"zip":10,"country":68,"countryCode":69,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"New Vector","Rustavi",{"type":56,"coordinates":83},[84,85],44.9787,41.56271,{"lat":85,"lon":84},[88],{"name":77,"role":43,"phone":10,"phoneExt":10,"email":78},{"facility":90,"status":51,"city":91,"state":10,"zip":10,"country":68,"countryCode":69,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Hepa+","Tbilisi",{"type":56,"coordinates":93},[94,95],44.83412,41.69143,{"lat":95,"lon":94},[98],{"name":77,"role":43,"phone":10,"phoneExt":10,"email":78},{"facility":100,"status":51,"city":101,"state":10,"zip":10,"country":102,"countryCode":10,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Mukikute","Dar es Salaam","Tanzania",{"type":56,"coordinates":104},[105,106],39.26951,-6.82349,{"lat":106,"lon":105},[109],{"name":110,"role":43,"phone":10,"phoneExt":10,"email":111},"Damali Kabwali","damalikabwali@gmail.com",{"facility":113,"status":51,"city":101,"state":10,"zip":10,"country":102,"countryCode":10,"cosmosGeoPoint":114,"geoPoint":116,"contacts":117},"Peer 2 Peer",{"type":56,"coordinates":115},[105,106],{"lat":106,"lon":105},[118],{"name":110,"role":43,"phone":10,"phoneExt":10,"email":111},{"facility":120,"status":51,"city":121,"state":10,"zip":10,"country":102,"countryCode":10,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Yovaribe","Ilala",{"type":56,"coordinates":123},[124,125],39.26667,-6.83333,{"lat":125,"lon":124},[128],{"name":110,"role":43,"phone":10,"phoneExt":10,"email":111},{"facility":130,"status":51,"city":131,"state":10,"zip":10,"country":102,"countryCode":10,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Mefada","Kinondoni",{"type":56,"coordinates":133},[134,135],39.2699,-6.78693,{"lat":135,"lon":134},[138],{"name":110,"role":43,"phone":10,"phoneExt":10,"email":111},{"facility":140,"status":51,"city":141,"state":10,"zip":10,"country":102,"countryCode":10,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"STEPS Tanzania","Ubungo",{"type":56,"coordinates":143},[144,145],39.2,-6.78333,{"lat":145,"lon":144},[148],{"name":110,"role":43,"phone":10,"phoneExt":10,"email":111},{"type":150,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[152,154,156,159,161,163,165,167,169,171,173],{"name":153,"class":6},"UNITAID",{"name":155,"class":6},"Burnet Institute",{"name":157,"class":158},"International Network of People who Use Drugs","UNKNOWN",{"name":160,"class":6},"University of Bristol",{"name":162,"class":6},"Frontline AIDS",{"name":164,"class":158},"Caritas",{"name":166,"class":158},"Drug-free and preventitve healthcare organisation Nigeria",{"name":168,"class":158},"National Viral Hepatitis and STI Control Program Nigeria",{"name":170,"class":6},"PATH",{"name":172,"class":6},"Population Services International",{"name":174,"class":6},"London School of Hygiene and Tropical Medicine","100546453","low-dead-space-injecting-equipment-distribution-program-for-people-who-inject-drugs-in-low--and-middle-income-countries-100546453",false,"NCT06395129","Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries","Implementing a Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries: a Process and Outcome Evaluation","Inclusion Criteria:\n\n* Aged ≥18 years (note that country-specific protocols may include participants aged ≥16 where appropriate and relevant);\n* Reporting a history of recent (past month) injection drug use;\n* Accessing the NSP to receive injecting equipment at either a facility, mobile service or through outreach and have an accompanying assigned program unique ID;\n* Able to understand and communicate in the local language(s);\n* If self-reporting HCV\u002FHIV negative status, interested in and agreeing to undergo HCV and HIV testing; and\n* Willing and able to provide informed consent to take part in the study.\n\nExclusion Criteria:\n\n* N\u002FA",true,"ALL","18 Years",{"count":186,"type":187},2400,"ESTIMATED","OBSERVATIONAL","Implementation and evaluation of a distribution program for low dead-space syringes\u002Fneedles (LDSS\u002FN) in Armenia, Georgia, and Tanzania, Egypt, Nigeria, Vietnam, India, Ukraine, and South Africa. This study aims to generate evidence on best practice LDSS\u002FN distribution programs which will enhance acceptability and sustain high levels of LDSS\u002FN uptake.\n\nPeople who inject drugs and access needle and syringe programs will be invited to attend up to three focus group discussion rounds (with 25 participants in each focus group round) to inform and provide feedback on a concurrent distribution program of LDSS\u002FN.\n\nThroughout distribution, a cohort study will be run alongside distribution with 240 participants enrolled per country (with the exception of Nigeria, where 480 participants will be recruited) who will undergo HIV and HCV testing and answer surveys on their sociodemographic and behavioral status. Key informant interviews will also be held with participating staff and stakeholders to evaluate the feasibility and acceptability of this program.\n\nPrimary outcomes assessed through this study include 1) community values and preferences for LDSS\u002FN, 2) barriers and facilitators to accessing LDSS\u002FN, 3) feasibility and effectiveness of the distribution program on increasing LDSS\u002FN uptake, 4) model the potential public health impact and cost effectiveness of LDSS\u002FN distribution in this setting.",[191,192,193],"Drug Use","Hepatitis","Hiv",[195,196,23,197,198,199,200,201,202,203,204,205,206,207],"Low dead-space needles and syringes","Qualitative interviews","High dead space needles\u002Fsyringes (HDSS\u002FN)","Rapid diagnostic test (RDT)","Feasibility","Acceptability","Cost effectiveness","Modelling","Focus group discussions","Harm Reduction","Values and preferences","Needle and syringe exchange program","Blood borne virus","2025-09-25",{"date":210,"type":211},"2025-10-01","ACTUAL",{"date":213,"type":211},"2024-09-13",{"date":215,"type":187},"2026-12",{"name":5,"class":6},9]